Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:53 AM
Ignite Modification Date:
2025-12-24 @ 11:53 AM
NCT ID:
NCT03504761
Eligibility Criteria:
Inclusion Criteria:
* Males \> 22 years old
* Patient scheduled for TRUS-guided prostate biopsy based on standard of care urologic requirements to assess for tissue malignancy (abnormal Digital Rectum Examination, Prostate Specific Antigen kinetics, age, ethnicity, family history, etc.)
* Enrolling physician must have expectation that prostate dimensions will meet minimum prostate volume and height requirements that will be evaluated at start of biopsy procedure (i.e., Prostate volume \> 20cc and height at least 22mm)
* Patient signs an Institutional Review Board approved, Informed Consent form to participate in the study prior to any study mandated determinations or procedure
Exclusion Criteria:
* Any anatomical or co-morbidity contraindications to TRUS prostate biopsy
* Acute painful perianal disorder (i.e. rectal abscess)
* Symptomatic, acute prostatitis
* Surgical absence of a rectum or the presence of a rectal fistula
* Patient has systemic infection or evidence of any surgical site infection (superficial or organ space), including active urinary tract infection
* Previous prostate intervention \[Transurethral Prostatectomy (TURP) (bipolar, monopolar, laser)\], Transurethral Microwave Thermotherapy (TUMT), High-Intensity Focused Ultrasound (HIFU), Cryo, Rezum, Urolift\], not including previous prostate biopsy
* Current use of blood thinning agents for medical comorbidity which prohibits the cessation of use as typically required per standard of care (SOC) or history of a bleeding disorder (e.g. coagulopathy)
* Prior pelvic irradiation
* Actively receiving therapy for the treatment of cancer (except for patients on 5-alpha reductase inhibitors, or non-melanoma skin cancers that are managed nonsystemically)
* Actively receiving intravesical therapy or within 6 months of treatment for bladder cancer
* Patient has compromised immune system
* Active inflammatory bowel disease within the last 6 months
* Any condition, or history of illness or surgery that, in the opinion of the Investigator, might confound the results of the study or pose additional risks to the patient (e.g. significant cardiovascular conditions or allergies)
* Patient is not likely to comply with the protocol or follow up evaluation
* Patient is participating in a clinical trial of another investigational drug or device that may impact participation in this clinical study
* Patient is unable to provide legal Informed Consent
Healthy Volunteers:
False
Sex:
MALE
Minimum Age:
22 Years
Study:
NCT03504761
Study Brief:
Protocol Section:
NCT03504761